Search clinical trials for: Peginterferon alfa-2b (pegIFN alfa-2b)

Total 857 results

Hoffmann-La Roche

Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Hepatitis C, Chronic

Brazil
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Hepatitis C

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Brazil
Hoffmann-La Roche

Completed

A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis B

Hepatitis B, Chronic

Belgium, United States, Israel, China, Australia, Germany, Russian Federation, Ukraine, United Kingdom, Poland, Bulgaria, Italy
Hoffmann-La Roche

Completed

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Russian Federation
National Taiwan University Hospital
Hoffmann-La Roche

Unknown

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Hepatitis C, Chronic | Hepatitis B, Chronic

Taiwan
Baqiyatallah Medical Sciences University
Guilan University of Medical Sciences; Baqiyatallah Research Center for Gastroenterology... and other collaborators

Completed

Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection

Hepatitis C | Thalassemia

Iran, Islamic Republic of
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Hoffmann-La Roche

Withdrawn

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Hepatitis C, Chronic
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
Merck Sharp & Dohme LLC

Withdrawn

A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)

Hepatitis B
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV

HIV Infections

Spain
Casa Sollievo della Sofferenza IRCCS

Completed

Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3) (genotype-3)

Chronic Hepatitis

Italy
Chinese University of Hong Kong

Completed

An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy

Chronic Hepaititis B

Hong Kong
Poitiers University Hospital

Completed

Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase

Chronic Phase of Chronic Myeloid Leukemia
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Hepatitis B, Chronic

Hong Kong, China
NORDynamIC Study Group

Completed

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Hepatitis C Virus

Sweden
National Taiwan University Hospital
National Science Council, Taiwan; National Health Research Institutes, Taiwan

Unknown

Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta

Chronic Hepatitis B | Chronic Hepatitis D

Taiwan
National Taiwan University Hospital
National Science Council, Taiwan

Unknown

Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B

Hepatitis B, Chronic

Taiwan
National Cancer Institute (NCI)

Completed

Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Centre Hospitalier Universitaire de Nice

Not yet recruiting

Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy (ALPHAGEM)

Membranous Nephropathy

France
Miguel Santín

Completed

Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients (CONTRA)

Chronic Hepatitis C

Spain
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Hoffmann-La Roche

Completed

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Solid Cancers

United States, Netherlands
The Methodist Hospital Research Institute
Schering-Plough

Terminated

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Carcinoma, Renal Cell

United States
John Kirkwood
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma (12-107)

Melanoma

United States
Hospital Carlos III, Madrid

Completed

Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies (PILOT-NR)

HIV Infections | Chronic Hepatitis C

Spain
Case Comprehensive Cancer Center

Completed

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

Renal Cell Cancer | Stage IV Renal Cell Cancer

United States
Hoffmann-La Roche

Withdrawn

A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

Hepatitis B, Chronic
Third Affiliated Hospital, Sun Yat-Sen University
Peking University; First People's Hospital of Foshan; Shenzhen Third People's...

Unknown

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Chronic Hepatitis B

China
Chang Gung Memorial Hospital

Terminated

Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
University of Ulm
Hoffmann-La Roche

Completed

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

Liver Diseases | Virus Diseases | Hepatitis C, Chronic

Germany
Hoffmann-La Roche

Completed

A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C

Hepatitis C

United States, United Kingdom, France, Canada, Spain, Italy, Germany
Foundation for Liver Research

Completed

Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders (SCIN-C)

Chronic Hepatitis C

Netherlands
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).

Hepatitis C, Chronic

United States, Puerto Rico
French National Agency for Research on AIDS and...

Unknown

Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Fibrosis | Hepatitis C, Chronic

France
University of North Carolina, Chapel Hill
Tibotec Pharmaceutical Limited

Completed

Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling

Hepatitis C

United States
Hoffmann-La Roche

Completed

A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)

Hepatitis C, Chronic

Czech Republic
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin (MK-2355-004)

Chronic Hepatitis C Infection
Merck Sharp & Dohme LLC

Completed

Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks (MK-2355-005)

Hepatitis C, Chronic
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Hoffmann-La Roche

Terminated

A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6

Hepatitis C, Chronic

Belgium
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Korea University Guro Hospital and other collaborators

Completed

Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

Chronic Hepatitis C

Korea, Republic of
Bristol-Myers Squibb

Completed

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (STRUCTURE)

Hepatitis C

France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States, Spain, Israel, Argentina, Poland
Janssen R&D Ireland

Completed

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients (QUEST-1)

Hepatitis C

United States, Australia, Ukraine, United Kingdom, Germany, Spain, Mexico, Canada, New Zealand, Russian Federation, Puerto Rico, Romania
Hoffmann-La Roche

Terminated

An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure

Hepatitis C, Chronic

Romania
Shanghai Cancer Hospital, China

Not yet recruiting

Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors

Thymic Epithelial Tumor

China
National Institute of Diabetes and Digestive and...

Completed

Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment

Chronic Hepatitis B

United States
Bristol-Myers Squibb

Completed

Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment (HEPCAT)

Hepatitis C Virus

Australia, France, Mexico, United States, Canada, Germany, Denmark, Italy, Puerto Rico, Sweden, Argentina

3

Subscribe